Home Cart Sign in  
Chemical Structure| 1798310-55-0 Chemical Structure| 1798310-55-0

Structure of AR420626
CAS No.: 1798310-55-0

Chemical Structure| 1798310-55-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3, GPR41), with an IC50 of 117 nM. It inhibits the motility changes induced by nicotine and serotonin in isolated rat colonic strips and suppresses serotonin-induced defecation in rats.

Synonyms: AR420626

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AR420626

CAS No. :1798310-55-0
Formula : C21H18Cl2N2O3
M.W : 417.29
SMILES Code : O=C(C1=C(C)NC2=C(C1C3=CC=CO3)C(CCC2)=O)NC4=CC(Cl)=CC=C4Cl
Synonyms :
AR420626
MDL No. :MFCD28987470
InChI Key :GGTYQECCGLBHGS-UHFFFAOYSA-N
Pubchem ID :91885415

Safety of AR420626

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of AR420626

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RIN-14B cells 10 µM 24 h To investigate the effect of AR420626 on 5-HT synthesis, results showed that AR420626 significantly upregulated TPH1 expression and promoted 5-HT production J Anim Sci Biotechnol. 2023 Aug 5;14(1):111
Caco-2 human colonic epithelial cells 50 µM 12 h To evaluate the effect of FFAR3 agonist on cytokine and LPS-induced IL-6 secretion. Results showed that AR420626 significantly enhanced IL-6 secretion. Nutrients. 2021 Aug 6;13(8):2716
RAW264.7 macrophages 20 µM 24 h To evaluate the inhibitory effect of FFAR3 agonist on LPS-induced NO production. Results showed that AR420626 significantly reduced NO secretion. Nutrients. 2021 Aug 6;13(8):2716
HLE cells 10, 25 µM 24, 48, 72 h Evaluate the effect of AR420626 on the proliferation of HLE cells, results showed that AR420626 significantly inhibited cell proliferation. Ther Adv Med Oncol. 2020 Mar 20;12:1758835920913432
HepG2 cells 10, 25 µM 24, 48, 72 h Evaluate the effect of AR420626 on the proliferation of HepG2 cells, results showed that AR420626 significantly inhibited cell proliferation. Ther Adv Med Oncol. 2020 Mar 20;12:1758835920913432
4T1 3-30 μM 24 h Evaluate the effect of AR420626 on 4T1 cell viability, showing significant inhibition at 3, 10, and 30 μM concentrations for 24 hours with ≈20% reduction. Am J Cancer Res. 2024 May 15;14(5):1999-2019
MCF-7 0.1-30 μM 24 h Evaluate the effect of AR420626 on MCF-7 cell viability, showing significant inhibition at 10 μM concentration for 24 hours. Am J Cancer Res. 2024 May 15;14(5):1999-2019
Rat proximal colon circular muscle strips 10 μM AR420626 inhibited nicotine- or serotonin-induced motility changes but had no effect on bethanechol-induced direct muscle contractions Neurogastroenterol Motil. 2018 Jan;30(1):10

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice 6-hydroxydopamine-induced Parkinson's disease model Intragastric administration 0.1 mg/kg Once daily for 8 weeks AR420626 mimicked the neuroprotective effects of propionate and improved motor deficits and dopaminergic neuronal loss Microbiome. 2021 Jan 31;9(1):34
C57BL/6 mice TNBS-induced colitis model Intraperitoneal injection 1 mg/kg Twice daily for 4 days To evaluate the therapeutic effect of AR420626 on TNBS-induced colitis. Results showed no significant improvement in macroscopic and biochemical parameters of colitis. Nutrients. 2021 Aug 6;13(8):2716
SHO nude mice HepG2 xenograft model Intraperitoneal injection 0.1 mg/kg (days 0-4), 0.2 mg/kg (days 7-11) Once daily on days 0-4 and days 7-11, for 18 days Evaluate the effect of AR420626 on the growth of HepG2 xenografts, results showed that AR420626 significantly inhibited tumor growth. Ther Adv Med Oncol. 2020 Mar 20;12:1758835920913432
Sprague-Dawley rats Exogenous serotonin-induced defecation model Intraperitoneal injection 0.1 mg/kg Single dose, observed for 6 hours AR420626 significantly suppressed serotonin-induced fecal output Neurogastroenterol Motil. 2018 Jan;30(1):10

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

11.98mL

2.40mL

1.20mL

23.96mL

4.79mL

2.40mL

References

 

Historical Records

Categories